Company intelligence / Profile preview
RIGImmune
Farmington, Connecticut, USArigimmune.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Pre-clinical studies demonstrate that RIG-101 can rapidly and substantially reduce viral loads by inducing innate immune responses when delivered directly to the respiratory tract. The company plans to enter Phase 1/2a clinical program in mid-2025 for the prevention of seasonal viral exacerbations of asthma[5].
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- RNA therapeuticsstem loop RNA therapeutics (SLRs)mRNA
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on RIGImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIGImmune.